TOTaisuke Obata

Taisuke Obata

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Taisuke Obata has a total of 18 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Acquiring Higher-Quality Pancreatic Neoplasm Tissue Samples Under Contrast-Enhanced Endoscopic Ultrasound-Guided Fine-Needle Biopsy

    by Hiroyuki Terasawa, Kazuyuki Matsumoto, Takehiro Tanaka, Hirofumi Inoue, Ryosuke Sato, Taisuke Obata, Akihiro Matsumi, Kazuya Miyamoto, Yuki Fujii, Daisuke Uchida, et al.

    Background: Comprehensive Genomic Profiling (CGP) requires sufficient tumor cellularity for successful next-generation sequencing. Pancreatic tumors often develop necrosis, which complicates sample collection. Contrast-enhanced endoscopic ultrasonography (CE-EUS) evaluates tumor viability, potentially improving sampling efficiency. We evaluated whether CE-EUS effectively increases the yield of tumor nuclei (TN) in endoscopic ultrasound-guided fine-needle biopsy (EUS-FNB) and improves CGP success rates. Methods: This prospective study included 44 pancreatic neoplasm patients undergoing EUS-FNB for CGP between November 2021 and March 2024. Tumors were classified as non-necrotic or necrotic on CE-EUS images. Tumors in the non-necrotic group were punctured twice at the center (group A), whereas those in the necrotic group were punctured twice from contrast-enhanced (group B) and non-contrast (group C) areas. Percent TN (%TN), tissue section area, DNA integrity number (DIN), DNA concentration, white tissue core length, and histological scores were compared among the three groups. Results: Necrosis was observed in 23 patients (53%). Groups A and B had significantly higher DNA concentrations than group C (group A [n=20]: 0.97 ng/μL; group B [n=23]: 0.42 ng/μL; and group C [n=23]: 0.22 ng/μL: A vs C, PConclusions: Tissue sampling using CE-EUS yielded high-quality specimens, suggesting that CE-EUS is a valuable technique for the treatment of CGP in cases of pancreatic neoplasms (Japan Registry of Clinical Trials no. 1062210071).

  • Open Access

    Double-blind randomized noninferiority study of the effect of pharyngeal lidocaine anesthesia on EUS

    by Yuki Fujii, Kazuyuki Matsumoto, Kei Harada, Nao Hattori, Ryosuke Sato, Taisuke Obata, Akihiro Matsumi, Kazuya Miyamoto, Daisuke Uchida, Shigeru Horiguchi, et al.

    Background and objectives: EUS is typically performed under sedation, often with concomitant analgesics to reduce pain. Traditionally used pharyngeal anesthesia, commonly with lidocaine, may cause pharyngeal discomfort and allergic reactions. This study investigated whether lidocaine-based pharyngeal anesthesia is necessary for EUS under sedation with analgesics. Methods: A double-blind, randomized, noninferiority study was conducted on EUS cases that met the selection criteria. Patients were randomly assigned to receive either 5 sprays of 8% lidocaine (lidocaine group: LG) or saline spray (placebo group: PG) as endoscopy pretreatment. The primary outcome was EUS tolerability, analyzed separately for endoscopists and patients, with a noninferiority margin set at 15%. Secondary outcomes included endoscopist and patient satisfaction, midazolam/pethidine doses, number of gag events, number of esophageal insertion attempts, use of sedative/analgesic antagonists, interruptions due to body movements, throat symptoms after endoscopy, and sedation-related adverse events. Results: Favorable tolerance was 85% in LG and 88% for PG among endoscopists (percent difference: 3.0 [95% confidence interval, −6.6 to 12.6]) and 90% in LG and 91% in PG among patients (percent difference, 0.94 [95% confidence interval, −7.5 to 9.4]). Both groups exceeded the noninferiority margin (P = 0.0002 for endoscopists and patients). Patient satisfaction was significantly higher in PG (P = 0.0080), but no intergroup differences were found in other secondary outcomes. Conclusions: PG was noninferior to LG for pharyngeal anesthesia during EUS with sedation and analgesics. These results suggest that pharyngeal anesthesia with lidocaine can be omitted when performing EUS under sedation with concomitant analgesics. Omitting pharyngeal anesthesia with lidocaine may prevent discomfort and complications caused by pharyngeal anesthesia, shorten examination times, and reduce medical costs.

  • Open Access

    Endoscopic Bridging Stent Placement Improves Bile Leaks After Hepatic Surgery

    by Taisuke Obata, Kazuyuki Matsumoto, Kei Harada, Nao Hattori, Ryosuke Sato, Akihiro Matsumi, Kazuya Miyamoto, Hiroyuki Terasawa, Yuki Fujii, Daisuke Uchida, et al.

    Background: Endoscopic treatment is one of the first-line treatments for bile leaks after hepatic surgery. However, detailed reports of endoscopic treatment for bile leaks after hepatic resection (HR) or liver transplantation (LT) are scarce. The outcomes of endoscopic treatment for bile leaks after hepatic surgery were examined, and factors related to successful treatment were identified. Methods: A total of 122 patients underwent endoscopic treatment for bile leaks after hepatic surgery. The diagnosis of a bile leak is based on the ISGLS criteria. The decision to perform endoscopic retrograde cholangiography (ERC) is made based on the amount of drainage output, laboratory data, clinical symptoms, and CT scan findings. In our study, the site of the bile leak was assessed using ERC. Endoscopic stents were placed to bridge across the bile leak site as much as possible. Otherwise, stents were placed near the leak site. Endoscopic stents were replaced every 2–3 months until an improvement in the bile leak was observed with or without biliary strictures. The outcomes of endoscopic treatment and the factors related to clinical success were evaluated. Results: Seventy-four patients with HR and forty-eight patients with LT were treated endoscopically. Technical and clinical success was achieved in 89% (109/122) and 82% (100/122) of patients, respectively. Three (2%) patients died from uncontrollable bile leaks. Bridging stent placement (p < 0.001), coexistent percutaneous drainage (p = 0.0025), and leak severity (p = 0.015) were identified as independent factors related to the clinical success of endoscopic treatment. During a median observation period of 1162 days after the achievement of clinical success, bile leak recurrence was observed in only three cases (3%). Conclusions: Endoscopic treatment is safe and effective for bile leaks after hepatic surgery. Bridging stent placement across the leak site is the most crucial factor for clinical success.